BIESF: AI 评分 48/100 — AI 分析 (4月 2026)

Biotest AG, a subsidiary of Grifols, S.A., develops, manufactures, and sells biological medicines, primarily in hematology, clinical immunology, and intensive care medicine. The company's products treat conditions like hemophilia, cytomegalovirus infections, and immune deficiencies.

Key Facts: AI Score: 48/100 Sector: Healthcare

公司概况

概要：

Biotest AG, a subsidiary of Grifols, S.A., operates in the biotechnology sector, developing and marketing biological medicines for hematology, clinical immunology, and intensive care. The company's focus on plasma-derived products and therapies for rare diseases positions it within a specialized segment of the global healthcare market, primarily serving Germany and international markets.

BIESF是做什么的？

Biotest AG, founded in 1946 and headquartered in Dreieich, Germany, is a biotechnology company specializing in the development, manufacture, and sale of biological medicines. Originally known as Biotest Serum-Institut GmbH, the company changed its name in 1986. Its core business revolves around plasma-derived products used in hematology, clinical immunology, and intensive care medicine. Key products include treatments for hemophilia A and B (Haemoctin, Vihuma, and Haemonine), therapies for cytomegalovirus infections (Cytotect CP biotest), and prophylaxis against hepatitis B (Fovepta and Hepatect). Additionally, Biotest offers Intratect and IgG Next Generation for immune deficiencies and autoimmune diseases, Varitect for varicella zoster virus infections, and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides products like Albiomin and Biseko for blood volume restoration, Cofact for clotting factor deficiencies, Fibrinogen for congenital fibrinogen deficiency, Trimodulin for pneumonia and COVID-19, and Pentaglobin for bacterial infections. As of January 21, 2022, Biotest AG operates as a subsidiary of Grifols, S.A., a global healthcare company and a leading producer of plasma-derived medicines.

BIESF的投资论点是什么？

Biotest AG, as a subsidiary of Grifols, presents a focused investment opportunity within the specialized field of plasma-derived therapies. The company's established product portfolio in hematology, immunology, and intensive care provides a stable revenue base. Growth catalysts include the potential expansion of existing product lines and the introduction of new therapies. However, the company's negative profit margin of -7.1% and high P/E ratio of -36.18 indicate potential challenges in achieving profitability. The company's beta of 0.00 suggests low volatility relative to the market. The dividend yield is 0.13%.

BIESF在哪个行业运营？

Biotest AG operates within the biotechnology industry, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market for plasma-derived therapies is driven by the increasing prevalence of chronic diseases, advancements in diagnostic technologies, and growing demand for specialized treatments. Biotest's focus on hematology, immunology, and intensive care positions it within specific segments of this market. Competitors include other biotechnology companies specializing in plasma-derived products and therapies for rare diseases. The industry is subject to regulatory oversight by agencies such as the European Medicines Agency (EMA) and other international regulatory bodies.

Biotechnology

Healthcare

BIESF有哪些增长机遇？

Expansion of Trimodulin for Community-Acquired Pneumonia (CAP) and COVID-19: Trimodulin represents a significant growth opportunity for Biotest AG. The global market for CAP treatment is projected to reach billions of dollars, while the ongoing need for COVID-19 therapies further expands the potential market. Biotest's clinical trials and regulatory approvals will be critical milestones in capturing this market share. Success in these areas could significantly boost revenue and market position.
Development of Novel Immunoglobulin Therapies: Biotest AG's focus on immunoglobulin therapies, such as Intratect and IgG Next Generation, presents a substantial growth opportunity. The global market for immunoglobulin therapies is expanding due to the increasing prevalence of immune deficiency disorders and autoimmune diseases. Biotest's research and development efforts in this area, coupled with successful clinical trials and regulatory approvals, could lead to the introduction of new and improved therapies, driving revenue growth.
Geographic Expansion into Emerging Markets: Biotest AG has the opportunity to expand its geographic presence into emerging markets, particularly in Asia and Latin America. These regions are experiencing growing demand for plasma-derived therapies due to increasing healthcare expenditure and improving access to healthcare services. By establishing partnerships, distribution networks, and regulatory approvals in these markets, Biotest can tap into new revenue streams and diversify its geographic footprint.
Strategic Partnerships and Acquisitions: Biotest AG can pursue strategic partnerships and acquisitions to expand its product portfolio, access new technologies, and strengthen its market position. Collaborations with other biotechnology companies, research institutions, and healthcare providers can accelerate the development and commercialization of new therapies. Acquisitions of complementary businesses can broaden Biotest's product offerings and geographic reach, creating synergies and enhancing shareholder value.
Advancements in Plasma Fractionation Technology: Investing in advanced plasma fractionation technologies can improve the efficiency and yield of plasma-derived products, reducing production costs and increasing profitability. By adopting innovative technologies such as membrane chromatography and continuous processing, Biotest can optimize its manufacturing processes and enhance its competitive advantage. These advancements can also lead to the development of new and improved plasma-derived therapies, further driving revenue growth.

Market capitalization of $1.60 billion reflects Biotest AG's current valuation within the biotechnology sector.
Negative P/E ratio of -36.18 indicates that the company is currently not profitable.
Gross margin of 20.1% shows the percentage of revenue exceeding the cost of goods sold.
Dividend yield of 0.13% provides a small return for investors.
Biotest AG operates as a subsidiary of Grifols, S.A., providing financial backing and strategic direction.

BIESF提供哪些产品和服务？

Develops biological medicines for hematology.
Manufactures biological medicines for clinical immunology.
Sells biological medicines for intensive care medicine.
Offers treatments for hemophilia A and B.
Provides therapies for cytomegalovirus infections.
Offers prophylaxis against hepatitis B.
Develops immunoglobulin therapies for immune deficiencies and autoimmune diseases.
Provides products for blood volume restoration and clotting factor deficiencies.

BIESF如何赚钱？

Develops and manufactures plasma-derived products.
Sells biological medicines directly to hospitals and healthcare providers.
Generates revenue through product sales in Germany and internationally.
Focuses on therapies for rare diseases and specialized medical conditions.

Hospitals and clinics.
Healthcare providers.
Patients with hematological disorders.
Patients with immunological disorders.
Patients in intensive care units.

Specialized expertise in plasma-derived therapies.
Established product portfolio in hematology, immunology, and intensive care.
Stringent regulatory approvals and compliance.
Proprietary manufacturing processes and technologies.

什么因素可能推动BIESF股价上涨？

Upcoming: Clinical trial results for Trimodulin in community-acquired pneumonia and COVID-19.
Upcoming: Regulatory approvals for new immunoglobulin therapies.
Ongoing: Expansion into emerging markets in Asia and Latin America.
Ongoing: Strategic partnerships and acquisitions to expand product portfolio.
Ongoing: Advancements in plasma fractionation technology to improve efficiency.

BIESF的主要风险是什么？

Potential: Competition from other biotechnology companies in the plasma-derived therapies market.
Potential: Stringent regulatory requirements and compliance costs.
Potential: Fluctuations in plasma supply and pricing.
Ongoing: Patent expirations and generic competition.
Ongoing: Negative profit margin and high P/E ratio.

BIESF的核心优势是什么？

Specialized expertise in plasma-derived therapies.
Established product portfolio in hematology, immunology, and intensive care.
Stringent regulatory approvals and compliance.
Operates as a subsidiary of Grifols, S.A.

BIESF的劣势是什么？

Negative profit margin.
High P/E ratio.
Dependence on plasma supply.
Limited geographic diversification.

BIESF有哪些机遇？

Expansion of Trimodulin for CAP and COVID-19.
Development of novel immunoglobulin therapies.
Geographic expansion into emerging markets.
Strategic partnerships and acquisitions.

BIESF面临哪些威胁？

Competition from other biotechnology companies.
Stringent regulatory requirements.
Fluctuations in plasma supply and pricing.
Patent expirations and generic competition.

BIESF的竞争对手是谁？

Biotest AG (different share class) — Shares of the same company with a different ticker. — (BITGF)
Kadmon Holdings Inc — Focuses on small molecules and biologics. — (CKDXF)
Chugai Pharmaceutical Co Ltd — Develops and markets pharmaceutical products. — (CMPUY)
Chugai Pharmaceutical Co Ltd — Develops and markets pharmaceutical products. — (CMPVF)
Daiichi Sankyo Co Ltd — Global pharmaceutical company with a broad portfolio. — (DWRKF)

Key Metrics

MoonshotScore: 48/100

Company Profile

CEO: Jorg Schuttrumpf
Headquarters: Dreieich, DE
Employees: 2,495
Founded: 2014

AI Insight

AI analysis pending for BIESF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Biotest AG do?

Biotest AG develops, manufactures, and sells biological medicines, primarily derived from plasma, for use in hematology, clinical immunology, and intensive care medicine. The company's product portfolio includes treatments for hemophilia, cytomegalovirus infections, hepatitis B, and immune deficiencies. Biotest AG operates as a subsidiary of Grifols, S.A., focusing on specialized therapies for rare diseases and critical medical conditions. The company's business model involves research and development, manufacturing, and commercialization of plasma-derived products to hospitals and healthcare providers in Germany and internationally.

What do analysts say about BIESF stock?

AI analysis is pending for BIESF. However, based on available financial data, Biotest AG has a market capitalization of $1.60 billion and a negative P/E ratio of -36.18, indicating that the company is currently not profitable. The gross margin is 20.1%, and the dividend yield is 0.13%. The company's beta is 0.00. these may be worth researching factors, as well as the company's position within the biotechnology industry and its relationship with parent company Grifols, S.A., when evaluating the stock.

What are the main risks for BIESF?

The main risks for Biotest AG include competition from other biotechnology companies in the plasma-derived therapies market, stringent regulatory requirements and compliance costs, fluctuations in plasma supply and pricing, patent expirations and generic competition, and the company's current negative profit margin and high P/E ratio. Additionally, as an OTC-listed stock, BIESF faces risks associated with limited financial disclosure, lower liquidity, and potential for fraud and manipulation. Investors should carefully consider these risks before investing in BIESF.